Stock News

Aeglea BioTherapeutics, Inc. (AGLE) Reaches $9.37 After 3.00% Up Move; Skba Capital Management Increased Chevron New (CVX) Position By $1.25 Million

Chevron Corporation (NYSE:CVX) Logo

The stock of Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) is a huge mover today! The stock increased 4.00% or $0.3601 during the last trading session, reaching $9.3701. About 55,260 shares traded. Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) has risen 26.34% since April 17, 2017 and is uptrending. It has outperformed by 14.79% the S&P500.The move comes after 7 months positive chart setup for the $156.63 million company. It was reported on Apr, 17 by Barchart.com. We have $9.65 PT which if reached, will make NASDAQ:AGLE worth $4.70 million more.

Skba Capital Management Llc increased Chevron Corp New (CVX) stake by 5.92% reported in 2017Q4 SEC filing. Skba Capital Management Llc acquired 10,000 shares as Chevron Corp New (CVX)’s stock declined 8.26%. The Skba Capital Management Llc holds 178,930 shares with $22.40 million value, up from 168,930 last quarter. Chevron Corp New now has $231.92B valuation. The stock increased 0.59% or $0.71 during the last trading session, reaching $121.41. About 2.37 million shares traded. Chevron Corporation (NYSE:CVX) has risen 7.88% since April 17, 2017 and is uptrending. It has underperformed by 3.67% the S&P500.

Skba Capital Management Llc decreased Abbvie Inc (NYSE:ABBV) stake by 15,700 shares to 126,425 valued at $12.23 million in 2017Q4. It also reduced Cisco Sys Inc (NASDAQ:CSCO) stake by 82,700 shares and now owns 613,930 shares. Conocophillips (NYSE:COP) was reduced too.

Among 35 analysts covering Chevron Corporation (NYSE:CVX), 26 have Buy rating, 0 Sell and 9 Hold. Therefore 74% are positive. Chevron Corporation had 119 analyst reports since August 4, 2015 according to SRatingsIntel. Jefferies maintained it with “Buy” rating and $130.0 target in Tuesday, August 29 report. The stock of Chevron Corporation (NYSE:CVX) earned “Buy” rating by Evercore on Tuesday, November 3. The firm has “Overweight” rating by PiperJaffray given on Tuesday, August 9. The rating was maintained by Barclays Capital with “Equal-Weight” on Tuesday, October 10. The firm has “Underperform” rating given on Friday, May 26 by BNP Paribas. Raymond James downgraded the stock to “Market Perform” rating in Tuesday, March 22 report. The firm earned “Overweight” rating on Wednesday, October 18 by Morgan Stanley. The firm earned “Neutral” rating on Thursday, January 21 by Simmons & Co. The stock of Chevron Corporation (NYSE:CVX) earned “Buy” rating by BMO Capital Markets on Thursday, June 22. The stock of Chevron Corporation (NYSE:CVX) has “Outperform” rating given on Thursday, December 15 by Macquarie Research.

Investors sentiment increased to 0.99 in Q4 2017. Its up 0.04, from 0.95 in 2017Q3. It is positive, as 51 investors sold CVX shares while 686 reduced holdings. 122 funds opened positions while 608 raised stakes. 1.19 billion shares or 0.58% more from 1.18 billion shares in 2017Q3 were reported. Delta Cap Mgmt Llc accumulated 2,470 shares. Fincl Bank Hapoalim Bm holds 1,640 shares. Pioneer Tru Bankshares N A Or reported 47,842 shares or 2.94% of all its holdings. Cullinan Assocs Inc has 77,821 shares. 7,556 were accumulated by Investment Prns Ltd Oh Adv. Wallington Asset Mngmt Ltd Liability stated it has 2,241 shares or 0.07% of all its holdings. Portfolio Solutions Lc holds 209 shares or 0% of its portfolio. Tocqueville Asset Mngmt Limited Partnership, New York-based fund reported 345,687 shares. Bessemer Gru stated it has 1.71 million shares. Ls Advisors Limited Co reported 138,408 shares. California State Teachers Retirement holds 3.57M shares or 0.92% of its portfolio. Patten Group holds 0.98% or 19,768 shares. Balasa Dinverno And Foltz Ltd Com invested in 0.33% or 17,969 shares. Blue Fincl Capital, Rhode Island-based fund reported 15,894 shares. Greylin Investment Mangement owns 10,249 shares or 0.28% of their US portfolio.

Analysts await Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) to report earnings on May, 8. They expect $-0.54 EPS, down 14.89% or $0.07 from last year’s $-0.47 per share. After $-0.38 actual EPS reported by Aeglea BioTherapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.11% negative EPS growth.

Chevron Corporation (NYSE:CVX) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *